OIG Advisory Opinion: 23-11

    Favorable

    Clinical trial subsidies for Medicare cost sharing + site/investigator payments

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG said this structure can be OK if site and investigator compensation is FMV and the patient subsidies are capped, not advertised, and applied consistently.

    ✓A device manufacturer paid Medicare cost-sharing obligations (up to $2,000) for clinical trial participants and paid sites/investigators for trial-related services.

    ✓OIG said this constitutes remuneration to both patients and providers, meaning Anti-Kickback and CMP risk was in play.

    ✓OIG accepted the structure as FAVORABLE because the payments were capped, not advertised, not expected to generate downstream use, and were certified as fair market value for necessary trial work.

    ✓Subsidizing cost-sharing helped preserve trial blinding and reduce socioeconomic barriers, which OIG saw as legitimate, non-referral-related reasons.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Have a certified third-party FMV basis for all site and investigator payments tied to trial activities.

    ✓Document that participant subsidies (e.g., cost-sharing coverage) are not advertised, not volume- linked, and capped.

    ✓Prove payments to providers are not contingent on enrollment or referral targets.

    ✓Show clear, written site agreements detailing responsibilities, capped compensation, and IRB oversight.

    If your trial support model can’t show FMV, capped subsidies, and a non-promotional purpose, OIG says you’re in risky territory.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    FAVORABLE

    OIG WATCH 23-11

    Clinical trial subsidies for Medicare cost sharing + site/investigator payments

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals